Proxy Votes Now

Home › Funds › Goldman Sachs › Goldman Sachs Multi-Strategy Alternatives Fund

Goldman Sachs Multi-Strategy Alternatives Fund (GIMMX) proxy voting record 2025-2026

Fund family: Goldman Sachs · Filed by Goldman Sachs Trust II (CIK 1557156) · SEC series S000040071

Share classes and tickers: GIMMX (C000124403), GMAMX (C000124400), GMCMX (C000124401), GMMFX (C000198936), GMMPX (C000201711), GSMMX (C000124402)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 2,173 with, 2 against, 2 abstentions (not counted as with management); 7 items carried no recommendation; 6 split votes are in neither count. Shareholder proposals: 1 FOR, 1 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Goldman Sachs as a whole

The same two figures as Goldman Sachs’s manager page (297,743 ballot items across 86 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsGoldman SachsItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)95.3%2,12294.3%240,212
Backed environmental and social shareholder proposals at US companiesn/a00.0%2,372

Where this fund voted differently from most Goldman Sachs funds

Each ballot item this fund voted is set against the votes of the other Goldman Sachs funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Goldman Sachs funds on 42 items (4.2% of the 993 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Goldman Sachs fundsMgmtResult
Guardant Health, Inc.2026-06-17Election of Class II Directors: Manuel Hidalgo MedinaForWITHHOLD — 16 of 16 Goldman Sachs fundsForElected, 75.5% support
Madrigal Pharmaceuticals, Inc.2026-06-17Re-election of Class I directors: Julian BakerWithholdFOR — 15 of 15 Goldman Sachs fundsAgainstElected, 88.6% support
Praxis Precision Medicines, Inc.2026-06-10To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: William YoungForWITHHOLD — 10 of 10 Goldman Sachs fundsForPassed (calculated), 85.5% support
Century Communities, Inc.2026-05-06To approve, on an advisory basis, our executive compensation.ForAGAINST — 9 of 9 Goldman Sachs fundsForApproved, 88.6% support
Alkermes plc2026-05-20To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.ForAGAINST — 7 of 7 Goldman Sachs fundsFor—
Clear Secure, Inc.2026-06-10Approval of an amendment to our Certificate of Incorporation to clarify the officer exculpation provision.ForAGAINST — 7 of 7 Goldman Sachs fundsForApproved, 99.5% support
Hut 8 Corp.2026-06-11To approve, on an advisory basis, the compensation of our named executive officers.AgainstFOR — 7 of 7 Goldman Sachs fundsAgainstApproved, 54.8% support
United Community Banks, Inc.2026-05-13To approve, on an advisory basis, the compensation of our named executive officers.ForAGAINST — 7 of 7 Goldman Sachs fundsForApproved, 95.9% support
Kontoor Brands, Inc.2026-04-23To elect six directors for a term ending at the 2027 annual meeting of shareholders: Robert K. ShearerAgainstFOR — 7 of 7 Goldman Sachs fundsAgainstPassed (calculated), 99.0% support
Applied Optoelectronics, Inc.2026-06-04To approve the 2026 equity incentive plan.AgainstFOR — 7 of 7 Goldman Sachs fundsAgainstPassed (calculated), 90.2% support
Viridian Therapeutics, Inc.2026-06-02To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Tomas KiselakWithholdFOR — 7 of 7 Goldman Sachs fundsAgainstElected, 83.3% support
CarGurus, Inc.2026-06-03To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers for 2025.AgainstFOR — 7 of 7 Goldman Sachs fundsAgainstApproved, 94.3% support
Hut 8 Corp.2026-06-11To approve an amendment to the Amended and Restated Hut 8 Corp. 2023 Omnibus Incentive Plan.AgainstFOR — 6 of 6 Goldman Sachs fundsAgainstApproved, 84.8% support
Belden Inc.2026-05-21Election of Directors: David J. AldrichAgainstFOR — 6 of 6 Goldman Sachs fundsAgainstPassed (calculated), 93.8% support
MKS Inc.2026-05-11The approval, on an advisory basis, of a Company proposal to reduce the threshold percentage of shareholders required to call a special meeting of shareholders from 40% to 25%.AbstainFOR — 5 of 5 Goldman Sachs fundsAgainstPassed (calculated), 98.5% support
Travere Therapeutics Inc.2026-05-19To approve the Company's 2018 Equity Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000 shares.ForAGAINST — 5 of 5 Goldman Sachs fundsForApproved, 96.3% support
MARA Holdings, Inc.2026-06-18A non-binding, advisory vote on the compensation of our Named Executive Officers ("Say-on-Pay").AgainstFOR — 5 of 5 Goldman Sachs fundsAgainstApproved, 59.1% support
Marqeta, Inc.2026-06-10To approve, on a non-binding advisory basis, the compensation of our named executive officers.AgainstFOR — 5 of 5 Goldman Sachs fundsAgainstPassed (calculated), 78.5% support
IonQ, Inc.2026-06-16To approve, on an advisory basis, the compensation of our named executive officers in 2025.AgainstFOR — 8 of 9 Goldman Sachs fundsAgainstApproved, 53.7% support
Abercrombie & Fitch Co.2026-06-03Election of Directors: Kerrii B. AndersonAgainstFOR — 4 of 4 Goldman Sachs fundsAgainstElected, 98.5% support
Chesapeake Utilities Corporation2026-05-06Approve, on an advisory non-binding basis, the compensation of the Company's Named Executive Officers.ForAGAINST — 4 of 4 Goldman Sachs fundsFor—
Assured Guaranty Ltd.2026-05-01Election of the following nominees as directors of Assured Guaranty Ltd. (the "Company") for a term expiring at the 2027 annual general meeting: Antonio Ursano, Jr.AgainstFOR — 4 of 4 Goldman Sachs fundsAgainstPassed (calculated), 91.4% support
Voyager Technologies, Inc.2026-05-29To approve an adjournment of the Annual Meeting, if necessary, to solicit addition proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 3.AgainstFOR — 4 of 4 Goldman Sachs fundsAgainst—
Voyager Technologies, Inc.2026-05-29To approve the Redomestication of the Company from Delaware to Texas.AgainstFOR — 4 of 4 Goldman Sachs fundsAgainstApproved, 92.3% support
TTM Technologies, Inc.2026-05-07To elect class II Directors: Julie S. EnglandForAGAINST — 3 of 3 Goldman Sachs fundsForElected, 86.0% support
Show all 42
Items 26 to 42.
CompanyMeetingItemThis fundMost Goldman Sachs fundsMgmtResult
Impinj, Inc.2026-05-28To approve, on an advisory basis, the compensation of our named executive officers.ForAGAINST — 3 of 3 Goldman Sachs fundsForApproved, 96.0% support
The Chefs' Warehouse, Inc.2026-05-08To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the 2026 Proxy Statement.AgainstFOR — 3 of 3 Goldman Sachs fundsAgainstApproved, 51.0% support
Solaris Energy Infrastructure, Inc.2026-05-15Approve, on a non-binding advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2025.AgainstFOR — 5 of 6 Goldman Sachs fundsAgainstPassed (calculated), 86.4% support
Simmons First National Corporation2026-05-13To adopt the following non-binding resolution approving the compensation of the named executive officers of the Company: "RESOLVED, that the compensation paid to the Company's named executive officers, as disclosed in the proxy statement pursuant to Item 402 of Regulation S-K, including the CompensaForAGAINST — 3 of 3 Goldman Sachs fundsForPassed (calculated), 89.7% support
OneSpaWorld Holdings Limited2026-06-03Election of Directors: Andrew R. HeyerWithholdFOR — 5 of 6 Goldman Sachs fundsAgainstPlurality election, 44.2% support
Inspire Medical Systems, Inc.2026-04-30Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal No. 5 and/or Proposal No. 6.ForAGAINST — 3 of 3 Goldman Sachs fundsForApproved, 94.4% support
Inspire Medical Systems, Inc.2026-04-30Approval of an amendment and restatement of the Inspire Medical Systems, Inc. 2018 Incentive Award Plan.ForAGAINST — 3 of 3 Goldman Sachs fundsForApproved, 62.0% support
Janux Therapeutics, Inc.2026-06-11To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.AgainstFOR — 3 of 3 Goldman Sachs fundsAgainstApproved, 90.3% support
Aeva Technologies, Inc.2026-06-18Election of Class II Directors: Hrach SimonianForWITHHOLD — 3 of 3 Goldman Sachs fundsFor—
MKS Inc.2026-05-11Shareholder A shareholder proposal to reduce the threshold percentage of shareholders required to call a special meeting of shareholders from 40% to 10%, if properly presented at the meeting.ForAGAINST — 4 of 5 Goldman Sachs fundsAgainstFailed (calculated), 32.6% support
Clearwater Analytics Holdings, Inc.2026-05-06To approve by, advisory (non-binding) vote, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the consummation of the Merger.ForAGAINST — 4 of 5 Goldman Sachs fundsForPassed (calculated), 97.7% support
First American Financial Corporation2026-05-12Advisory vote to approve executive compensation.ForAGAINST — 5 of 8 Goldman Sachs fundsFor—
Matador Resources Company2026-06-11Advisory vote to approve the compensation of the Company's named executive officersForAGAINST — 4 of 6 Goldman Sachs fundsForApproved, 96.1% support
UniFirst Corporation2025-12-15Shareholder To elect two Class II directors, each to serve for a term of three years until the 2029 annual meeting of shareholders and until their respective successors are duly elected and qualified: Arnaud AjdlerForWITHHOLD — 2 of 3 Goldman Sachs funds—Not elected, 68.5% support
UniFirst Corporation2025-12-15Shareholder To elect two Class II directors, each to serve for a term of three years until the 2029 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael A. CroattiForWITHHOLD — 2 of 3 Goldman Sachs funds—Not elected, 71.7% support
UniFirst Corporation2025-12-15To elect two Class II directors, each to serve for a term of three years until the 2029 annual meeting of shareholders and until their respective successors are duly elected and qualified: Joseph M. NowickiWithholdFOR — 2 of 3 Goldman Sachs funds—Elected, 21.4% support
UniFirst Corporation2025-12-15To elect two Class II directors, each to serve for a term of three years until the 2029 annual meeting of shareholders and until their respective successors are duly elected and qualified: Steven S. SintrosWithholdFOR — 2 of 3 Goldman Sachs funds—Elected, 27.2% support

Download all 42 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 95.1% of this fund’s 2,177 such votes could be given a sector; the other 107 (4.9%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Finance51300.0%
Health Care46400.0%
Consumer Discretionary27100.0%
Industrials21010.5%
Technology19910.5%
Energy11300.0%
Utilities11100.0%
Real Estate7900.0%
Basic Materials5800.0%
Consumer Staples3000.0%
Miscellaneous2200.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections1,5280
Say-on-Pay2650
Audit-related2620
Compensation740
Corporate Governance411
Capital Structure180
Shareholder Rights and Defenses141
Extraordinary Transactions100
Other Social Issues10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Bloom Energy CorporationMay 21, 2026$2M80
Marqeta, Inc.June 10, 2026$2M80
Magnite, Inc.June 8, 2026$2M60
AAON, Inc.May 12, 2026$2M70
Eastern Bankshares, Inc.May 18, 2026$2M80
The Chefs' Warehouse, Inc.May 8, 2026$2M110
American Healthcare REIT, Inc.June 24, 2026$2M110
Ameris BancorpMay 21, 2026$2M120

Notable votes against management

MeetingCompanyProposalFundMgmt
May 11, 2026MKS Inc.A shareholder proposal to reduce the threshold percentage of shareholders required to call a special meeting of shareholders from 40% to 10%, if properly presented at the meeting. Shareholder proposalForAgainst
June 3, 2026Power Integrations, Inc.To consider, if properly presented at the Annual Meeting, a stockholder proposal related to the separation of the office of Chairman of the Board and the office of Chief Executive Officer. Shareholder proposalAgainstFor

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

2,213 ballot items at 266 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Goldman Sachs Multi-Strategy Alternatives Fund (GIMMX) voted at 266 shareholder meetings of 262 companies, on 2,213 ballot items in all. Where management made a recommendation, the fund followed it on 99.8% of the items and voted against it 2 times. Its most frequent area of disagreement was corporate governance (1 of its votes against management). It voted on 4 shareholder proposals. It voted FOR the board's own proposals more often than Goldman Sachs's funds as a whole (95.3% against 94.3%). It voted differently from most Goldman Sachs funds on 42 items. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Goldman Sachs’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.